Identification and characterization of novel recombinant vaccine antigens for immunization against genitalChlamydia trachomatis
Open Access
- 1 March 2009
- journal article
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 55 (2), 258-270
- https://doi.org/10.1111/j.1574-695x.2008.00527.x
Abstract
Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection worldwide, with over 91 million cases estimated annually. An effective subunit vaccine against Chlamydia may require a multivalent subunit cocktail of antigens in a single formulation for broad coverage of a heterogeneous major histocompatibility complex population. Herein, we describe the identification of novel C. trachomatis antigens by CD4+ and CD8+ T-cell expression cloning, serological expression cloning, and an in silico analysis of the C. trachomatis genome. These antigens elicited human CD4+ T-cell responses, and a subset proved to be immunogenic and protective when administered as immunoprophylactic vaccines against C. trachomatis challenge. Candidate vaccines consisting of the prioritized C. trachomatis antigens adjuvanted in a GlaxoSmithKline proprietary AS01B adjuvant were prioritized based on induction of solid protection against challenge in C57BL/6 and BALB/c mice with C. trachomatis. Some of the vaccines prevented bacterial shedding and colonization of the upper genital tract to varying degrees by mechanisms that may include CD4+ T cells.Keywords
This publication has 42 references indexed in Scilit:
- The Protective Effect of Antibody in Immunity to Murine Chlamydial Genital Tract Reinfection Is Independent of Immunoglobulin AInfection and Immunity, 2005
- Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analysesInternational Journal of Epidemiology, 2004
- Immunization with the Chlamydia trachomatis Mouse Pneumonitis Major Outer Membrane Protein by Use of CpG Oligodeoxynucleotides as an Adjuvant Induces a Protective Immune Response against an Intranasal Chlamydial ChallengeInfection and Immunity, 2002
- Induction of Protective Immunity againstChlamydia trachomatisGenital Infection by a Vaccine Based on Major Outer Membrane Protein–Lipophilic Immune Response-Stimulating ComplexesInfection and Immunity, 2000
- Studies in Knockout Mice Reveal that Anti‐Chlamydial Protection Requires TH1 Cells Producing IFN‐γ: Is this True for Humans?Scandinavian Journal of Immunology, 1997
- Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infectionVaccine, 1995
- Identification of a CD4+ T cell-stimulating antigen of pathogenic bacteria by expression cloning.The Journal of Experimental Medicine, 1995
- Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitisJournal of General Microbiology, 1993
- Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane proteinJournal of General Microbiology, 1992
- Chlamydial vaccines—Future trendsJournal of Infection, 1992